Madrigal Pharmaceuticals
We're hiring — explore open roles below and apply in a few clicks.
Location
Headquarters: Conshohocken, Pennsylvania, United States, North America
Region: Pennsylvania
Country: US
Continent: North America
About
Madrigal Pharmaceuticals is a biopharmaceutical company focused on developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need. Its research aims to halt or reverse liver fibrosis and treat MASH to prevent progression to cirrhosis, liver failure, or transplantation. The company highlights FDA-approved treatment in MASH and communicates a commitment to advancing care for patients affected by lipid-related liver disorders. Headquartered in the United States, Madrigal emphasizes science-driven innovation and leadership in hepatology research.
Madrigal Pharmaceuticals is a biopharmaceutical company developing treatments for metabolic dysfunction-associated steatohepatitis (MASH). Its FDA-approved therapy targets adults with moderate to advanced liver fibrosis, and it is conducting Phase 3 trials for patients with compensated cirrhosis. The company focuses on halting or reversing liver fibrosis to prevent disease progression.
Madrigal Pharmaceuticals, Inc.
2016
for_profit
active
Industries
Primary Industry: Business Services
Categories
Funding & Financials
Public Company
737200000
200m-1b
ipo
NASDAQ:MDGL
nasdaq
Investors
Founders
Rebecca Taub
Leadership
Rebecca Taub — Founder, Director and CMO, President R&D at Madrigal Pharmaceuticals
Rita Thakkar — Sr. Vice President and Chief Accounting Officer
Alex Howarth — Chief Financial Officer
Carole Huntsman — Chief Commercial Officer (CCO)
Dominic F. Labriola — Chief Data and Analytics Officer
Ronald Filippo — Chief Information Officer
Technology Stack
Products
Resmetirom: An orally administered, liver-directed thyroid hormone receptor-beta (THR-β) agonist approved for treating adults with metabolic dysfunction-associated steatohepatitis (MASH).
Funding rounds
Post Ipo Debt · $350M · (2025-07-22) · Lead: Blue Owl
Post Ipo Equity · $690M · (2024-03-18)
Post Ipo Equity · $500M · (2023-09-28)
